References
- National Institute for Health and Clinical Excellence. Clinical knowledge summaries. Hypothyroidism. NICE, UK; last revised June 2018. Available at: https://cks.nice.org.uk/hypothyroidism [Last accessed September 2018]
- Jonklaas J, Bianco AC, Bauer AJ et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid 2014;24:1670–751.
- Frellick M. Top-selling, top-prescribed drugs for 2016. Medscape; October 2, 2017. Available at https://www.medscape.com/viewarticle/886404 [Last accessed September 2018]
- Medicines and Healthcare products Regulatory Agency. Levothyroxine tablet products: a review of clinical & quality considerations. MHRA, UK; 2013. Available at: www.gov.uk/government/publications/levothyroxine-a-review-of-clinical-and-quality-considerations [Last accessed February 22, 2016]
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: levothyroxine sodium tablets – in vivo pharmacokinetic and bioavailability studies and in vitro dissolution testing; CDER; 2000. Available at: www.fda.gov/cder/guidance/index.htm [Last accessed February 22, 2016]
- Shah RB, Collier JS, Sayeed VA, et al. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS Pharm Sci Tech 2010;11:1359–67
- The United States Pharmacopeial Convention. 2009 Current USP monograph of levothyroxine sodium tablets. Revision Bulletin, Official; US, February 1, 2010. Available at: http://www.usp.org/sites/default/files/usp-pdf/EN/USPNF/levothyroxineSodiumTablet.pdf [Last accessed September 2010]
- Agence Française de Sécrurité Sanitaire des Produits de Santé 2012. Commission Nationale de Pharmacovigilance. Compte rendu de la réunion du mardi 27 Mars 2012, France. Available at: https://ansm.sante.fr/var/ansm_site/storage/original/application/4e4d2a70e5dddfb150fe87360d6b13dd.pdf [Last accessed September 2012]
- Medicines and Health Regulatory Authority. Levothyroxine tablet products: a review of clinical & quality considerations. MHRA, UK; January 7, 2013. Available at: http://webarchive.nationalarchives.gov.uk/20141205150130/http:/www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con222566.pdf (Last accessed September 2018]
- European Medicines Agency. Committee for Proprietary medicinal Products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. UK; 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003519.pdf [Last accessed September 2018]
- Rothacker KM, Brown SJ, Hadlow NC, et al. Reconciling the log-linear and non-log-linear nature of the TSH-free T4 relationship: intra-individual analysis of a large population. J Clin Endocrinol Metab 2016;101:1151–8
- European Medicines Agency. Committee For Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1 (January 2010), UK. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (Last accessed September 2018)
- Davit B, Braddy AC, Conner DP, et al. International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences. AAPS J 2013;15:974–90
- World Health Organization. WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 863 - Thirty-fourth Report. Switzerland, 1996. Available at: http://apps.who.int/medicinedocs/en/d/Js5516e/4.html (Last accessed October 2018]
- Euthyrox Prescribing Information, Merck KGaA, Germany; 2017.
- Zarbock, SD, Magnuson B, Hoskins L, et al. Lactose: the hidden culprit in medication intolerance? Othopedics 2007;30:1–3
- Gottwald-Hostalek U, Uhl W, Wolna P, et al. New levothyroxine formulation meeting 95–105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin 2017;33:169–74
- Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest 2017;40:1289–301
- Cellini M, Santaguida MG, Gatto I, et al. Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J Clin Endocrinol Metab 2014;99:E1454–8
- Jubiz W, Ramirez M. Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. J Clin Endocrinol Metab 2014;99:E1031–4
- Taylor PN, Razvi S, Pearce SH, et al. Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013;98:3562–71
- Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249–52
- Green WL. New questions regarding bioequivalence of levothyroxine preparations: a clinician’s response. AAPS J 2005;7:E54–8
- Reverter JL, Colomé E. Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma. Endocrinol Nutr 2011;58:75–83
- Montalto M, Gallo A, Santoro L, et al. Low-dose lactose in drugs neither increases breath hydrogen excretion nor causes gastrointestinal symptoms. Aliment Pharmacol Ther 2008;28:1003–12
- Montalto M, Gallo A, Gasbarrini A, et al. Lactose in drugs: avoided or allowed to lactose maldigesters? Aliment Pharmacol Ther 2010;31:924–5